The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

References

• CazzolaMCalzettaLOraJPuxedduERoglianiPMateraMGSearching for the synergistic effect between aclidinium and formoterol: from bench to bedsideRespir Med2015109101305131126303336
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLPageCPPharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchiEur J Pharmacol201474513514325446566
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLPuxedduEPharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cellsRespir Res20161717027296533
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLSegretiAFaccioloFRoglianiPMateraMGTranslational study searching for synergy between glycopyrronium and indacaterolCOPD201512217518125222881
   PubMedGoogle Scholar
• CalzettaLRoglianiPMatteiMPharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchiCOPD201714552653228745522
   PubMedGoogle Scholar
• DonohueJFSinghDMunzuCKilbrideSChurchAMagnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trialsRespir Med2016112657426797016
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPFaccioloFRendinaECazzolaMMateraMGPharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchiEur J Pharmacol201781214715428716723
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGCazzolaMPharmacological interaction between LABAs and LAMAs in the airways: optimizing synergyEur J Pharmacol201576116817325981302
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPMateraMGEscalation and de-escalation of therapy in COPD: myths, realities and perspectivesDrugs201575141575158526316169
   PubMed Web of Science ®Google Scholar
• MateraMGRoglianiPCalzettaLCazzolaMSafety considerations with dual bronchodilator therapy in COPD: an updateDrug Saf201639650150826924197
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPMateraMGCazzolaMA systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPDChest201614951181119626923629
   PubMed Web of Science ®Google Scholar
• JansenJPNaciHIs network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiersBMC Med201311115923826681
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGGroup PPreferred reporting items for systematic reviews and meta-analyses: the PRISMA StatementOpen Med200933e123e13021603045
   PubMedGoogle Scholar
• MoherDShamseerLClarkeMPreferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statementSyst Rev201541125554246
   PubMed Web of Science ®Google Scholar
• RoglianiPCalzettaLCavalliFMateraMGCazzolaMPirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysisPulm Pharmacol Ther2016409510327481628
   PubMed Web of Science ®Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev20143CD010844
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPOraJPuxedduECazzolaMMateraMGLABA/LAMA combination in COPD: a meta-analysis on the duration of treatmentEur Respir Rev20172614316004328096283
   PubMed Web of Science ®Google Scholar
• RodrigoGJPriceDAnzuetoALABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysisInt J Chron Obstruct Pulmon Dis20171290792228360514
   PubMed Web of Science ®Google Scholar
• HigginsJPTGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0The Cochrane Collaboration2011 Available from: www.cochrane-handbook.orgAccessed June 14, 2017
   Google Scholar
• RoglianiPCalzettaLCazzolaMMateraMGDrug safety evaluation of roflumilast for the treatment of COPD: a meta-analysisExpert Opin Drug Saf20161581133114627279341
   PubMed Web of Science ®Google Scholar
• GuyattGOxmanADAklEAGRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tablesJ Clin Epidemiol201164438339421195583
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLPageCInfluence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysisEur Respir Rev20152413745146126324807
   PubMed Web of Science ®Google Scholar
• ShenYCaiWLeiSZhangZEffect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysisCOPD201411335135824378052
   PubMedGoogle Scholar
• CalzettaLMateraMGBraidoFWithdrawal of inhaled corticosteroids in COPD: a meta-analysisPulm Pharmacol Ther20174514815828606478
   PubMed Web of Science ®Google Scholar
• GuevaraJPBerlinJAWolfFMMeta-analytic methods for pooling rates when follow-up duration varies: a case studyBMC Med Res Methodol2004411715248899
   PubMedGoogle Scholar
• DeCosterJMeta-analysis notes2004 Available from: http://www.stat-help.com/meta.pdfAccessed June 14, 2017
   Google Scholar
• TurnerJRDurhamTAMeta-methodology: conducting and reporting meta-analysesJ Clin Hypertens (Greenwich)2014162919324734310
   PubMed Web of Science ®Google Scholar
• CalzettaLRoncadaPdi CaveDPharmacological treatments in asthma-affected horses: a pair-wise and network meta-analysisEquine Vet J201749671071728295526
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPOraJPuxedduECazzolaMGabriella MateraMLABA/LAMA combination in COPD: a meta-analysis on the duration of treatmentEur Respir Rev20172614316004328096283
   PubMed Web of Science ®Google Scholar
• LuGAdesAEAssessing evidence inconsistency in mixed treatment comparisonsJ Am Statist Assoc2006101474447459
   Web of Science ®Google Scholar
• SpiegelhalterDJAbramsKRMylesJPBayesian Approaches to Clinical Trials and Health-Care Evaluation13ChichesterWiley2004
   Google Scholar
• van ValkenhoefGLuGde BrockBHillegeHAdesAEWeltonNJAutomating network meta-analysisRes Synth Methods20123428529926053422
   PubMed Web of Science ®Google Scholar
• ValkenhoefGDiasSAdesAEWeltonNJAutomated generation of node-splitting models for assessment of inconsistency in network meta-analysisRes Synth Methods201671809326461181
   PubMed Web of Science ®Google Scholar
• DiasSWeltonNJSuttonAJCaldwellDMLuGAdesAEEvidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trialsMed Decis Making201333564165623804508
   PubMed Web of Science ®Google Scholar
• WallaceBCDahabrehIJTrikalinosTALauJTrowPSchmidCHClosing the gap between methodologists and end-users: R as a computational back-endJ Statist Software2012495115
   Web of Science ®Google Scholar
• D’UrzoARennardSKerwinEA randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary diseaseRespir Med2017125394828340861
   PubMed Web of Science ®Google Scholar
• DonohueJFSoongWWuXShresthaPLeiALong-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPDRespir Med2016116414827296819
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res201415112325756831
   PubMed Web of Science ®Google Scholar
• MahlerDAKerwinEAyersTFLIGHT: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with COPDAm J Respir Crit Care Med201592910681079
   Web of Science ®Google Scholar
• WatzHMailanderCBaierMKirstenAEffects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)BMC Pulm Med20161619527301417
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority studyThorax201570431131925677679
   PubMed Web of Science ®Google Scholar
• O’DonnellDECasaburiRFrithPEffects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPDEur Respir J2017494160134828424359
   PubMed Web of Science ®Google Scholar
• IchinoseMKatoMTakizawaALong-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary diseaseRespir Investig2017552121129
   Web of Science ®Google Scholar
• TroostersTBourbeauJMaltaisFEnhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study designBMJ Open201664e010106
   Web of Science ®Google Scholar
• BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• SilerTMDonaldACO’DellDChurchAFahyWAA randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 µg on health-related quality of life in patients with COPDInt J Chron Obstruct Pulmon Dis20161197197927274218
   PubMed Web of Science ®Google Scholar
• ZhengJZhongNNewlandsAChurchAGohAHEfficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled studyInt J Chron Obstruct Pulmon Dis2015101753176726366068
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• MartinezFJRabeKFFergusonGTEfficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPDChest2017151234035727916620
   PubMed Web of Science ®Google Scholar
• HananiaNATashkinDPKerwinEMLong-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension Delivery Technology in patients with chronic obstructive pulmonary diseaseRespir Med201712610511528427541
   PubMed Web of Science ®Google Scholar
• SalantiGIndirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis toolRes Synth Methods201232809726062083
   PubMed Web of Science ®Google Scholar
• ChengJPullenayegumEMarshallJKIorioAThabaneLImpact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation studyBMJ Open201668e010983
   PubMed Web of Science ®Google Scholar
• LanePWMeta-analysis of incidence of rare eventsStat Methods Med Res201322211713222218366
   PubMed Web of Science ®Google Scholar
• ScichiloneNBasileMBattagliaSBelliaVWhat proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?Respiration2014871111724281343
   PubMed Web of Science ®Google Scholar
• TraversJMarshSCaldwellBExternal validity of randomized controlled trials in COPDRespir Med200710161313132017113277
   PubMed Web of Science ®Google Scholar
• CharlesCNew options for optimal bronchodilation in chronic obstructive pulmonary diseaseEMJ Respir201425866
   Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
   PubMed Web of Science ®Google Scholar
• MateraMGCalzettaLCazzolaMβ-adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectivesDrugs201373151653166324127222
   PubMed Web of Science ®Google Scholar
• RicciardoloFLBlasiFCentanniSRoglianiPTherapeutic novelties of inhaled corticosteroids and bronchodilators in asthmaPulm Pharmacol Ther20153311026014510
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCMateraMGLong-acting muscarinic receptor antagonists for the treatment of respiratory diseasePulm Pharmacol Ther201326330731723274274
   PubMed Web of Science ®Google Scholar
• BuhlRBanerjiDProfile of glycopyrronium for once-daily treatment of moderate-to-severe COPDInt J Chron Obstruct Pulmon Dis2012772974123118536
   PubMed Web of Science ®Google Scholar
• SegretiACalzettaLRoglianiPCazzolaMUmeclidinium for the treatment of chronic obstructive pulmonary diseaseExpert Rev Respir Med20148666567125312239
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPMateraMGAclidinium bromide for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother20131491205121423566013
   PubMed Web of Science ®Google Scholar
• D’UrzoADKerwinEMChapmanKRSafety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing dataInt J Chron Obstruct Pulmon Dis2015101599161226316734
   PubMed Web of Science ®Google Scholar
• ZhangPMendeUFunctional role, mechanisms of regulation, and therapeutic potential of regulator of G protein signaling 2 in the heartTrends Cardiovasc Med2014242859323962825
   PubMed Web of Science ®Google Scholar
• LiuYSunLPanZOverexpression of M(3) muscarinic receptor is a novel strategy for preventing sudden cardiac death in transgenic miceMol Med20111711–121179118721785809
   PubMed Web of Science ®Google Scholar
• MateraMGRoglianiPCazzolaMMuscarinic receptor antagonists for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother201415796197724669979
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300121439145018812535
   PubMed Web of Science ®Google Scholar
• MuthumalaADrenosFElliottPMHumphriesSERole of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysisEur J Heart Fail200810131318158268
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGDonnerCFInhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung diseaseDrugs200565121595161016060696
   PubMed Web of Science ®Google Scholar
• RoglianiPCalzettaLCoppolaAOptimizing drug delivery in COPD: the role of inhaler devicesRespir Med201712461428284323
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLRoglianiPMateraMGTiotropium formulations and safety: a network meta-analysisTher Adv Drug Saf201781173028203364
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• European CommissionA guideline on summary of product characteristics (SmPC)2009 Available from: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdfAccessed June 22, 2017
   Google Scholar